Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on August 12, 2020. The filing reports financial results for the three and six months ended June 30, 2020, along with recent corporate updates. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol SLRX.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It serves as a notification that these results were reported via a press release (Exhibit 99.1) incorporated by reference, but the actual figures are not present in the 8-K body text.
Material Changes
The filing does not detail specific material changes versus prior periods within the text provided. It references a press release for the full details of the financial results and corporate updates.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be deemed incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Verify the correct registrant name is Salarius Pharmaceuticals, Inc., not Decoy Therapeutics Inc.
- Review Exhibit 99.1 (the Press Release) to obtain actual financial figures for the three and six months ended June 30, 2020.
- Confirm the trading symbol SLRX on the Nasdaq Capital Market.
- Note that the financial data in this specific 8-K text is not "filed" for liability purposes under Section 18 of the Exchange Act.